Jefferies lifts Corcept Therapeutics Incorporated [CORT] price estimate. Who else is bullish?

Corcept Therapeutics Incorporated [NASDAQ: CORT] surged by $0.34 during the normal trading session on Tuesday and reaching a high of $15.94 during the day while it closed the day at $15.69. The company report on August 4, 2020 that Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended June 30, 2020.

Financial Highlights .

Corcept Therapeutics Incorporated stock has also loss -1.63% of its value over the past 7 days. However, CORT stock has inclined by 18.50% in the 3 months of the year. Over the past six months meanwhile, it has gained 20.32% and gained 29.67% year-on date.

The market cap for CORT stock reached $1.93 billion, with 114.58 million shares outstanding and 103.26 million shares in the current float. Compared to the average trading volume of 1.02M shares, CORT reached a trading volume of 1120726 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Corcept Therapeutics Incorporated [CORT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CORT shares is $16.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CORT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Corcept Therapeutics Incorporated shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 24, 2019. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on September 06, 2019, representing the official price target for Corcept Therapeutics Incorporated stock. Previously, the target price had yet another drop from $22 to $12, while B. Riley FBR kept a Neutral rating on CORT stock. On August 10, 2018, analysts decreased their price target for CORT shares from 20 to 11.

The Average True Range (ATR) for Corcept Therapeutics Incorporated is set at 0.66, with the Price to Sales ratio for CORT stock in the period of the last 12 months amounting to 5.77. The Price to Book ratio for the last quarter was 4.39, with the Price to Cash per share for the same quarter was set at 2.49. Price to Free Cash Flow for CORT in the course of the last twelve months was 13.36 with Quick ratio for the last quarter at 10.00.

CORT stock trade performance evaluation

Corcept Therapeutics Incorporated [CORT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.63. With this latest performance, CORT shares dropped by -6.16% in over the last four-week period, additionally plugging by 20.32% over the last 6 months – not to mention a rise of 23.93% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CORT stock in for the last two-week period is set at 47.61, with the RSI for the last a single of trading hit 44.27, and the three-weeks RSI is set at 48.37 for Corcept Therapeutics Incorporated [CORT]. The present Moving Average for the last 50 days of trading for this stock 15.96, while it was recorded at 15.64 for the last single week of trading, and 13.76 for the last 200 days.

Corcept Therapeutics Incorporated [CORT]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Corcept Therapeutics Incorporated [CORT] shares currently have an operating margin of +36.41 and a Gross Margin at +98.20. Corcept Therapeutics Incorporated’s Net Margin is presently recorded at +30.73.

Return on Total Capital for CORT is now 34.31, given the latest momentum, and Return on Invested Capital for the company is 29.02. Return on Equity for this stock inclined to 29.11, with Return on Assets sitting at 26.02. When it comes to the capital structure of this company, Corcept Therapeutics Incorporated [CORT] has a Total Debt to Total Equity ratio set at 0.93. Additionally, CORT Total Debt to Total Capital is recorded at 0.92, with Total Debt to Total Assets ending up at 0.84. Long-Term Debt to Equity for the company is recorded at 0.51, with the Long-Term Debt to Total Capital now at 0.51.

Reflecting on the efficiency of the workforce at the company, Corcept Therapeutics Incorporated [CORT] managed to generate an average of $457,189 per employee. Receivables Turnover for the company is 16.34 with a Total Asset Turnover recorded at a value of 0.85.Corcept Therapeutics Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.00 and a Current Ratio set at 10.10.

Earnings per share (EPS) analysis for Corcept Therapeutics Incorporated [CORT] stock

With the latest financial reports released by the company, Corcept Therapeutics Incorporated posted 0.22/share EPS, while the average EPS was predicted by analysts to be reported at 0.2/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CORT.

Corcept Therapeutics Incorporated [CORT]: Insider Ownership positions

There are presently around $1,387 million, or 78.70% of CORT stock, in the hands of institutional investors. The top three institutional holders of CORT stocks are: BLACKROCK INC. with ownership of 15,244,767, which is approximately -4.242% of the company’s market cap and around 3.40% of the total institutional ownership; VANGUARD GROUP INC, holding 11,117,827 shares of the stock with an approximate value of $174.44 million in CORT stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $130.27 million in CORT stock with ownership of nearly 6.882% of the company’s market capitalization.

Positions in Corcept Therapeutics Incorporated stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 113 institutional holders increased their position in Corcept Therapeutics Incorporated [NASDAQ:CORT] by around 8,462,228 shares. Additionally, 97 investors decreased positions by around 8,966,082 shares, while 32 investors held positions by with 70,968,352 shares. The mentioned changes placed institutional holdings at 88,396,662 shares, according to the latest SEC report filing. CORT stock had 35 new institutional investments in for a total of 2,441,273 shares, while 36 institutional investors sold positions of 1,159,601 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam